PTCT Quote, Financials, Valuation and Earnings

Krystal Biotech has a net margin of 73.68% compared to PTC Therapeutics's net margin of 40.52%. PTC Therapeutics's return on equity of -- beat Krystal Biotech's return on equity of 13.91%.

PTC Therapeutics has a consensus price target of $62.81, signalling upside risk potential of 29.43%. On the other hand Krystal Biotech has an analysts' consensus of $208.00 which suggests that it could grow by 38.53%. Given that Krystal Biotech has higher upside potential than PTC Therapeutics, analysts believe Krystal Biotech is more attractive than PTC Therapeutics.

PTC Therapeutics has a beta of 0.501, which suggesting that the stock is 49.905% less volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.514%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $1.2B, which are larger than Krystal Biotech quarterly revenues of $88.2M. PTC Therapeutics's net income of $866.6M is higher than Krystal Biotech's net income of $35.7M. Notably, PTC Therapeutics's price-to-earnings ratio is 7.45x while Krystal Biotech's PE ratio is 36.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 2.17x versus 13.44x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 73.68% compared to PTC Therapeutics's net margin of -49.65%. PTC Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

PTC Therapeutics has a consensus price target of $62.81, signalling upside risk potential of 29.43%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that NovaBay Pharmaceuticals has higher upside potential than PTC Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than PTC Therapeutics.

PTC Therapeutics has a beta of 0.501, which suggesting that the stock is 49.905% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $1.2B, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. PTC Therapeutics's net income of $866.6M is higher than NovaBay Pharmaceuticals's net income of $7.7M. Notably, PTC Therapeutics's price-to-earnings ratio is 7.45x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 2.17x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of 73.68% compared to PTC Therapeutics's net margin of --. PTC Therapeutics's return on equity of -- beat Oragenics's return on equity of --.

PTC Therapeutics has a consensus price target of $62.81, signalling upside risk potential of 29.43%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 1998.11%. Given that Oragenics has higher upside potential than PTC Therapeutics, analysts believe Oragenics is more attractive than PTC Therapeutics.

PTC Therapeutics has a beta of 0.501, which suggesting that the stock is 49.905% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $1.2B, which are larger than Oragenics quarterly revenues of --. PTC Therapeutics's net income of $866.6M is higher than Oragenics's net income of -$2.2M. Notably, PTC Therapeutics's price-to-earnings ratio is 7.45x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 2.17x versus 0.46x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 73.68% compared to PTC Therapeutics's net margin of --. PTC Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

PTC Therapeutics has a consensus price target of $62.81, signalling upside risk potential of 29.43%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1367.51%. Given that Theriva Biologics has higher upside potential than PTC Therapeutics, analysts believe Theriva Biologics is more attractive than PTC Therapeutics.

PTC Therapeutics has a beta of 0.501, which suggesting that the stock is 49.905% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

PTC Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PTC Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

PTC Therapeutics quarterly revenues are $1.2B, which are larger than Theriva Biologics quarterly revenues of --. PTC Therapeutics's net income of $866.6M is higher than Theriva Biologics's net income of -$4.3M. Notably, PTC Therapeutics's price-to-earnings ratio is 7.45x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PTC Therapeutics is 2.17x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.